Literature DB >> 11881526

Bevacizumab. Anti-VEGF monoclonal antibody, avastin, rhumab-VEGF.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11881526     DOI： 10.2165/00126839-200203010-00006

Source DB:  PubMed          Journal:  Drugs R D        ISSN： 1174-5886


× No keyword cloud information.
  10 in total

Review 1.  Use of bevacizumab in recurrent glioblastoma.

Authors:  Ashley Ghiaseddin; Katherine B Peters
Journal:  CNS Oncol       Date:  2015-04-23

2.  Role of vascular endothelial growth factor inhibitors in the treatment of gynecologic malignancies.

Authors:  Robert A Burger
Journal:  J Gynecol Oncol       Date:  2010-03-31       Impact factor: 4.401

3.  Efficacy of combination treatment modalities for intermediate and advanced hepatocellular carcinoma: intra-arterial therapies, sorafenib and novel small molecules.

Authors:  Julio A Gutierrez; Robert G Gish
Journal:  Transl Cancer Res       Date:  2013-12       Impact factor: 1.241

4.  Evolution of laparoscopic left lateral sectionectomy without the Pringle maneuver: through resection of benign and malignant tumors to living liver donation.

Authors:  Roberto Ivan Troisi; Jacques Van Huysse; Frederik Berrevoet; Bert Vandenbossche; Mauricio Sainz-Barriga; Alessio Vinci; Salvatore Ricciardi; Tommaso Bocchetti; Xavier Rogiers; Bernard de Hemptinne
Journal:  Surg Endosc       Date:  2010-06-08       Impact factor: 4.584

5.  Comparing the effectiveness and costs of Bevacizumab to Ranibizumab in patients with Diabetic Macular Edema: a randomized clinical trial (the BRDME study).

Authors:  A M E Schauwvlieghe; G Dijkman; J M Hooymans; F D Verbraak; C B Hoyng; M G W Dijkgraaf; R Van Leeuwen; J R Vingerling; A C Moll; Reinier O Schlingemann
Journal:  BMC Ophthalmol       Date:  2015-07-07       Impact factor: 2.209

Review 6.  Intravitreal bevacizumab as anti-vascular endothelial growth factor in the management of complications of proliferative diabetic retinopathy.

Authors:  J Fernando Arevalo
Journal:  Med Hypothesis Discov Innov Ophthalmol       Date:  2013

7.  Inhibitory effect of carboplatin in combination with bevacizumab on human retinoblastoma in an in vitro and in vivo model.

Authors:  Qi Zhang; Yong Cheng; Lvzhen Huang; Yujing Bai; Jianhong Liang; Xiaoxin Li
Journal:  Oncol Lett       Date:  2017-08-25       Impact factor: 2.967

8.  IgG Conformer's Binding to Amyloidogenic Aggregates.

Authors:  Monichan Phay; Alfred T Welzel; Angela D Williams; Helen P McWilliams-Koeppen; Veronika Blinder; Tiernan T O'Malley; Alan Solomon; Dominic M Walsh; Brian O'Nuallain
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

9.  RAIN-Droplet: a novel 3D in vitro angiogenesis model.

Authors:  Benjamin D Zeitlin; Zhihong Dong; Jacques E Nör
Journal:  Lab Invest       Date:  2012-05-07       Impact factor: 5.662

10.  Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study.

Authors:  A M E Schauwvlieghe; G Dijkman; J M Hooymans; F D Verbraak; C B Hoyng; M G W Dijkgraaf; T Peto; J R Vingerling; R O Schlingemann
Journal:  PLoS One       Date:  2016-05-20       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.